XBiotechXBIT
Market Cap: $199M
About: XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Employees: 94
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
1.11% more ownership
Funds ownership: 13.72% [Q1] → 14.83% (+1.11%) [Q2]
3% more call options, than puts
Call options by funds: $30K | Put options by funds: $29K
0% more funds holding
Funds holding: 46 [Q1] → 46 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
32% less capital invested
Capital invested by funds: $33.9M [Q1] → $23.2M (-$10.7M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for XBIT.